Correlation between CA125 levels after sixth cycle of chemotherapy and clinical outcome in advanced ovarian carcinoma

abstract

       AIM:

To correlate CA125 levels after platinum- and paclitaxel-based chemotherapy with progression-free survival (PFS) and overall survival (OS) in advanced ovarian carcinoma following primary cytoreduction.

MATERIALS AND METHODS:
The study was conducted on 247 patients.

RESULTS:
By log-rank test, PFS and OS were related to performance status (PS), residual disease, ascites and post-chemotherapy CA125 using 10.8 U/ml as cut-off . PFS was related to post-chemotherapy CA125 assay (cut-off values of 7.1 U/ml, 18.5 U/ml and 35.0 U/ml. OS was related to FIGO stage (p=0.02). On multivariate analysis, residual disease, ascites and post-chemotherapy CA125 with any selected cut-off were independent prognostic variables for PFS, whereas residual disease, PS and post-chemotherapy CA125 (10.8 U/ml as cut-off) were independent prognostic variables for OS.

CONCLUSION:
Post-operative CA125 using 10.8 U/ml as cut-off was an independent prognostic variable for both PFS and OS.